Lycopodium alkaloids: Pharmacology

Natural Products: Phytochemistry, Botany and Metabolism of Alkaloids, Phenolics and Terpenes

Volumn , Issue , 2013, Pages 1239-1262

  Olafsdóttir, Elín Soffía ^a   Halldorsdottir, Elsa S ^a   Pich, N M ^a   Omarsdottir, S ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

Author keywords

Acetylcholinesterase; Alzheimer s disease; Biological activity; Clinical trials; Clubmosses; Huperzine A; Lycopodiaceae; Lycopodiumalka oids; Pharmacology

Indexed keywords

EID: 84939654060     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-22144-6_42     Document Type: Chapter

References (91)

1. Willis KJ, McElwain JC (2002) The evolution of plants. Oxford University Press, Oxford
2. Kukkonen I (2000) Lycopsida. In: Jonsell B (ed) Flora Nordica, Vol 1. Bergius Foundation, Stockholm
3. Ma XQ, Tan CH, Zhu DY, Gang DR, Xiao PG (2007) Huperzine a from Huperzia species-an ethnopharmacolgical review. J Ethnopharmacol 113(1):15-34. doi:10.1016/j.jep.2007.05.030
4. Ching RC (1978) The Chinese fern families and genera: systematic arrangement and historical origin. Acta Phytotax Sin 16:1-9
5. Ollgaard B (1989) Index of the Lycopodiaceae. Royal Danish Academy of Sciences and Letters, Copenhagen
6. Ayer WA, Trifonov LS (1994) Lycopodium alkaloids. The alkaloids: chemistry and pharmacology, Vol 45. Academic, New York
7. Hirasawa Y, Kobayashi J, Morita H (2009) The Lycopodium alkaloids. Heterocycles 77(2):679-729. doi:10.3987/rev-08-sf(r)6
8. Ma XQ, Gang DR (2004) The Lycopodium alkaloids. Nat Prod Rep 21(6):752-772. doi:10.1039/b409720n
9. MacLean DB (1985) Lycopodium alkaloids. In: Brossi A (ed) The alkaloids, Vol 26. Academic, New York, pp 241-296
10. Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: past, present, and future. J Clin Invest 116(11):2843-2854. doi:10.1172/jci29894
11. Wang J, Zhang HY, Tang XC (2010) Huperzine A Improves chronic inflammation and cognitive decline in rats with cerebral hypoperfusion. J Neurosci Res 88(4):807-815. doi:10.1002/jnr.22237
12. Wang Y, Huang LQ, Tang XC, Zhang HY (2010) Retrospect and prospect of active principles from Chinese herbs in the treatment of dementia. Acta Pharmacol Sin 31(6):649-664. doi:10.1038/aps.2010.46
13. Liu JS, Zhu YL, Yu CM, Zhou YZ, Han YY, Wu FW, Qi BF (1986) The structures of huperzine-A and huperzine-B, 2 new alkaloids exhibiting marked anticholinesterase activity. Can J Chem-Revue Canadienne De Chimie 64(4):837-839. doi:10.1139/v86-137
14. Liu JS, Yu CM, Zhou YZ, Han YY, Wu FW, Qi BF, Zhu YL (1986) Study on the chemistry of huperzine-A and huperzine-B. Acta Chim Sin 44(10):1035-1040
15. Staerk D, Larsen J, Larsen LA, Olafsdottir ES, Witt M, Jaroszewski JW (2004) Selagoline, a new alkaloid from Huperzia selago. Nat Prod Res 18(3):197-203. doi:10.1080/14786410310001620600
16. Ayer WA, Browne LM, Orszanska H, Valenta Z, Liu JS (1989) Alkaloids of Lycopodium selago-on the identity of selagine with huperzine-A and the structure of a related alkaloid. Can J Chem-Revue Canadienne De Chimie 67(10):1538-1540. doi:10.1139/v89-234
17. Ha GT, Wong RK, Zhang Y (2011) Huperzine A as potential treatment of Alzheimer’s disease: an assessment on chemistry, pharmacology, and clinical studies. Chem Biodivers 8(7):1189-1204. doi:10.1002/cbdv.201000269
18. Bodeker K (1881) Lycopodin, das erste Alkaloid der Gefasskryptogamen. Justus Liebigs Ann Chem 208(3):363-367. doi:10.1002/jlac.18812080308
19. Harrison WA, Curcumelli-Rodostamo M, Carson DF, Barclay LRC, MacLean DB (1961) Lycopodium alkaloids: X. The structure of lycopodine. Can J Chem 39(10):2086-2099. doi:10.1139/v61-277
20. MacLean DB (1968) Lycopodium alkaloids. In: Manske RHF (ed) The alkaloids, Vol 10. Academic, New York, pp 305-382
21. Ayer WA (1991) The lycopodium alkaloids. Nat Prod Rep 8(5):455-463. Doi 10.1039/np9910800455
22. Terry AV, Buccafusco JJ (2003) The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306(3):821-827. doi:10.1124/jpet.102.041616
23. Bartus RT (2000) On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163(2):495-529. doi:10.1006/exnr.2000.7397
24. Auld DS, Kornecook TJ, Bastianetto S, Quirion R (2002) Alzheimer’s disease and the basal forebrain cholinergic system: relations to b-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 68(3):209-245. doi:10.1016/s0301-0082(02)00079-5
25. Howes MJR, Perry E (2011) The role of phytochemicals in the treatment and prevention of Dementia. Drug Aging 28(6):439-468
26. Zhang HY, Yan H, Tang XC (2008) Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase. Cell Mol Neurobiol 28(2):173-183. doi:10.1007/s10571-007-9163-z
27. Terry AV Jr, Callahan PM, Hall B, Webster SJ (2011) Alzheimer’s disease and age-related memory decline (preclinical). Pharmacol Biochem Behav 99(2):190-210. doi:10.1016/j.pbb.2011.02.002
28. Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256(3):183-194. doi:10.1111/j.1365-2796.2004.01388.x
29. Sellal F, Nieoullon A, Michel G, Michel BF, Lacomblez L, Geerts H, Stula AD, Bordet R, Bentue-Ferrer D, Allain H (2005) Pharmacology of Alzheimer’s disease: appraisal and prospects. Dement Geriatr Cogn Disord 19(5-6):229-245. doi:10.1159/000084400
30. Dvir H, Jiang HL, Wong DM, Harel M, Chetrit M, He XC, Jin GY, Yu GL, Tang XC, Silman I, Bai DL, Sussman JL (2002) X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-Huperzine A and (-)-huperzine B: structural evidence for an active site rearrangement. Biochemistry 41(35):10810-10818. doi:10.1021/bi020151
31. Tang XC (1996) Huperzine A shuangyiping: a promising drug for Alzheimer’s disease. Zhongguo Yao Li Xue Bao 17:481-484
32. Alzheimer’s Association. http://www.alz.org/alzheimers_disease_alternative_treatments.asp. Accessed 12 Sep 2011
33. Tun MKM, Wustmann D-J, Herzon SB (2011) A robust and scalable synthesis of the potent neuroprotective agent (-)-huperzine A. Chemical Science 2:2251-2253. Doi: 10.1039/c1sc00455g
34. Ma XQ, Gang DR (2008) In vitro production of huperzine A, a promising drug candidate for Alzheimer’s disease. Phytochemistry 69(10):2022-2028. doi:10.1016/j.phytochem.2008.04.017
35. Wang Y, Zeng QG, Bin Zhang Z, Yan RM, Wang LY, Zhu D (2011) Isolation and characterization of endophytic huperzine A-producing fungi from Huperzia serrata. J Ind Microbiol Biotechnol 38(9):1267-1278. doi:10.1007/s10295-010-0905-4
36. Quinn DM (1987) Acetylcholinesterase-enzyme structure, reaction dynamics, and virtual transition-states. Chem Rev 87(5):955-979. doi:10.1021/cr00081a005
37. Silman I, Sussman JL (2005) Acetylcholinesterase: ‘classical’ and ‘non-classical’ functions and pharmacology. Curr Opin Pharmacol 5(3):293-302. doi:10.1016/j.coph.2005.01.014
38. Liang YQ, Tang XC (2004) Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats. Neurosci Lett 361(1-3):56-59. doi:10.1016/j.neulet.2003.12.071
39. Raves ML, Harel M, Pang YP, Silman I, Kozikowski AP, Sussman JL (1997) Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat Struc Biol 4(1):57-63. doi:10.1038/nsb0197-57
40. Koellner G, Kryger G, Millard CB, Silman I, Sussman JL, Steiner T (2000) Active-site gorge and buried water molecules in crystal structures of acetylcholinesterase from Torpedo californica. J Mol Biol 296(2):713-735. doi:10.1006/jmbi.1999.3468
41. Xu YC, Shen JH, Luo XM, Silman I, Sussman JL, Chen KX, Jiang HL (2003) How does Huperzine A enter and leave the binding gorge of acetylcholinesterase? Steered molecular dynamics simulations. J Am Chem Soc 125(37):11340-11349. doi:10.1021/ja029775t
42. Xu YC, Colletier JP, Weik M, Jiang HL, Moult J, Silman I, Sussman JL (2008) Flexibility of aromatic residues in the active-site gorge of acetylcholinesterase: X-ray versus molecular dynamics. Biophys J 95(5):2500-2511. doi:10.1529/biophysj.108.129601
43. Ellman GL, Courtney KD, Andres V Jr, Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7(2):88-95. doi:10.1016/0006-2952(61)90145-9
44. Zhao Q, Tang XC (2002) Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine. Eur J Pharmacol 455(2-3):101-107. doi:10.1016/s0014-2999(02)02589-x
45. Feng S, Wang ZF, He XC, Zheng SX, Xia Y, Jiang HL, Tang XC, Bai DL (2005) Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. J Med Chem 48(3):655-657. doi:10.1021/jm0496178
46. Hirasawa Y, Monta H, Shiro M, Kobayashi J (2003) Sieboldine A, a novel tetracyclic alkaloid from Lycopodium sieboldii, inhibiting acetylcholinesterase. Org Lett 5(21):3991-3993. doi:10.1021/ol035560s
47. Choo CY, Hirasawa Y, Karimata C, Koyama K, Sekiguchi M, Kobayashi J, Morita H (2007) Carinatumins A-C, new alkaloids from Lycopodium carinatum inhibiting acetylcholinesterase. Bioorg Med Chem 15(4):1703-1707. doi:10.1016/j.bmc.2006.12.005
48. Katakawa K, Nozoe A, Kogure N, Kitajima M, Hosokawa M, Takayama H (2007) Fawcettimine-related alkaloids from Lycopodium serratum. J Nat Prod 70(6):1024-1028. doi:10.1021/np0700568
49. Koyama K, Hirasawa Y, Kobayashi J, Morita H (2007) Cryptadines A and B, novel C27N3-type pentacyclic alkaloids from Lycopodium cryptomerinum. Bioorg Med Chem 15(24):7803-7808. doi:10.1016/j.bmc.2007.08.043
50. Halldorsdottir ES, Jaroszewski JW, Olafsdottir ES (2010) Acetylcholinesterase inhibitory activity of lycopodane-type alkaloids from the Icelandic Lycopodium annotinum ssp. alpestre. Phytochemistry 71(2-3):149-157. doi:10.1016/j.phytochem.2009.10.018
51. The plant list. http://www.theplantlist.org. Accessed 22 Sep 2011
52. Ved HS, Koenig ML, Dave JR, Doctor BP (1997) Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. NeuroReport 8(4):963-967
53. Gordon RK, Nigam SV, Weitz JA, Dave JR, Doctor BP, Ved HS (2001) The NMDA receptor ion channel: a site for binding of huperzine A. J Appl Toxicol 21:S47-S51. doi: 10.1002/jat.805
54. Wang XD, Chen XQ, Yang HH, Hu GY (1999) Comparison of the effects of cholinesterase inhibitors on H-3 MK-801 binding in rat cerebral cortex. Neurosci Lett 272(1):21-24. doi:10.1016/s0304-3940(99)00567-4
55. Wang XD, Zhang JM, Yang HH, Hu GY (1999) Modulation of NMDA receptor by huperzine A in rat cerebral cortex. Acta Pharmacol Sin 20(1):31-35
56. Zhang Y-H, Chen X-Q, Yang H-H, Jin G-Y, Bai D-L, Hu G-Y (2000) Similar potency of the enantiomers of huperzine A in inhibition of [3 H]dizocilpine (MK-801) binding in rat cerebral cortex. Neurosci Lett 295(3):116-118. doi:10.1016/s0304-3940(00)01615-3
57. Zhang HY, Tang XC (2006) Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol Sci 27(12):619-625. doi:10.1016/j.tips.2006.10.004
58. Zhang HY, Liang YQ, Tang XC, He XC, Bai DL (2002) Stereoselectivities of enantiomers of huperzine A in protection against beta-amyloid(25-35)-induced in PC12 and NG108-15 cells and cholinesterase inhibition in mice. Neurosci Lett 317(3):143-146. doi:10.1016/s0304-3940(01)02437-5
59. Harborne JB, Baxter H, Moss GP (1999) Phytochemical dictionary: a handbook of bioactive compounds from plants. Taylor & Francis, London
60. Marier G, Bernard R (1948) Etude des proprietes pharmacologiques de l’annotinine et de la lycopodine. Can J Res 26e(1):174-181. doi:10.1139/cjr48e-003
61. Wang H, Tang XC (1998) Anticholinesterase effects of huperzine A, E2020, and tacrine in rats. Zhongguo Yao Li Xue Bao 19(1):27-30
62. Little JT, Walsh S, Aisen PS (2008) An update on huperzine A as a treatment for Alzheimer’s disease. Expert Opin Investig Drug 17(2):209-215. doi:10.1517/13543784.17.2.209
63. Zangara A (2003) The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer’s disease. Pharmacology Biochem Behav 75(3):675-686. doi:10.1016/s0091-3057(03)00111-4
64. Wang BS, Wang H, Wei ZH, Song YY, Zhang L, Chen HZ (2009) Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis. J Neural Transm 116(4):457-465. doi:10.1007/s00702-009-0189-x
65. Wang R, Yan H, Tang XC (2006) Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 27(1):1-26. doi:10.1111/j.1745-7254.2006.00255.x
66. Li YX, Zhang RQ, Li CR, Jiang XH (2007) Pharmacokinetics of huperzine A following oral administration to human volunteers. Eur J Drug Metab Pharmacokinet 32(4):183-187
67. Wu T, Li CY, Chen M, Zhang J, Tan HS, Yang C, Ju WZ (2011) Clinic pharmacokinetic profiles of huperzine A following transdermal administration to healthy human volunteers. Chromatographia 74(1-2):67-73. doi:10.1007/s10337-011-2037-z
68. Ye JC, Zeng S, Zheng GL, Chen GS (2008) Pharmacokinetics of huperzine A after transdermal and oral administration in beagle dogs. Int J Pharmaceut 356(1-2):187-192. doi:10.1016/j.ijpharm.2008.01.007
69. Wang Q, Chen GS (2009) Pharmacokinetic behavior of huperzine A in plasma and cerebrospinal fluid after intranasal administration in rats. Biopharm Drug Dispos 30(9):551-555. doi:10.1002/bdd.686
70. Yue P, Tao T, Zhao Y, Ren J, Chai X (2007) Huperzine A in rat plasma and CSF following intranasal administration. Int J Pharmaceut 337(1-2):127-132. doi:10.1016/j.ijpharm.2006.12.029
71. Tang XC, Desarno P, Sugaya K, Giacobini E (1989) Effect of huperzine-A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J Neurosci Res 24(2):276-285. doi:10.1002/jnr.490240220
72. Ma X, Wang H, Xin J, Zhang T, Tu Z (2003) Identification of cytochrome P450 1A2 as enzyme involved in the microsomal metabolism of Huperzine A. Eur J Pharmacol 461(2-3):89-92. doi:10.1016/s0014-2999(03)01290-1
73. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270(1):414-423
74. Omiecinski CJ, Remmel RP, Hosagrahara VP (1999) Concise review of the cytochrome P450s and their roles in toxicology. Toxicol Sci 48(2):151-156. doi:10.1093/toxsci/48.2.151
75. Ma XC, Wang HX, Xin J, Zhang T, Tu ZH (2003) Effects of huperzine A on liver cytochrome P-450 in rats. Acta Pharmacol Sin 24(8):831-835
76. Wilkinson D, Roughan L (2007) The BRAINz trial: a novel approach to acetylcholinesterase-inhibitor treatment for Alzheimer’s disease. Future Neurol 2(4):379-382. doi:10.2217/14796708.2.4.379
77. Bajgar J, Fusek J, Kassa J, Kuca K, Jun D (2009) Chemical aspects of pharmacological prophylaxis against nerve agent poisoning. Curr Med Chem 16(23):2977-2986
78. Wang Y, Wei Y, Oguntayo S, Jensen N, Doctor B, Nambiar M (2011) [+]-Huperzine A protects against Soman toxicity in guinea pigs. Neurochem Res. doi:10.1007/s11064-011-0564-5, 1-10
79. Lallement G, Baille V, Baubichon D, Carpentier P, Collombet JM, Filliat P, Foquin A, Four E, Masqueliez C, Testylier G, Tonduli L, Dorandeu F (2002) Review of the value of huperzine as pretreatment of organophosphate poisoning. Neurotoxicology 23(1):1-5. doi:10.1016/s0161-813x(02)00015-3
80. Eckert S, Eyer P, Worek F (2007) Reversible inhibition of acetylcholinesterase by carbamates or huperzine A increases residual activity of the enzyme upon soman challenge. Toxicology 233(1-3):180-186. doi:10.1016/j.tox.2006.09.012
81. Gordon RK, Haigh JR, Garcia GE, Feaster SR, Riel MA, Lenz DE, Aisen PS, Doctor BP (2005) Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman. Chem-Biol Interact 157-158:239-246. doi:10.1016/j.cbi.2005.10.031
82. Ainge GD, Lorimer SD, Gerard PJ, Ruf LD (2002) Insecticidal activity of huperzine A from the New Zealand clubmoss, Lycopodium varium. J Agric Food Chem 50(3):491-494. doi:10.1021/jf0106087
83. Morita H, Hirasawa Y, Shinzato T, Kobayashi J (2004) New phlegmarane-type, cernuane-type, and quinolizidine alkaloids from two species of Lycopodium. Tetrahedron 60(33): 7015-7023. doi:10.1016/j.tet.2003.09.106
84. Koyama K, Morita H, Hirasawa Y, Yoshinaga M, Hoshino T, Obara Y, Nakahata N, Kobayashi J (2005) Lannotinidines A-G, new alkaloids from two species of Lycopodium. Tetrahedron 61(15):3681-3690. doi:10.1016/j.tet.2005.02.016
85. Ishiuchi K, Kubota T, Mikami Y, Obara Y, Nakahata N, Kobayashi J (2007) Complanadines C and D, new dimeric alkaloids from Lycopodium complanatum. Bioorg Med Chem 15(1):413-417. doi:10.1016/j.bmc.2006.09.043
86. Hirasawa Y, Morita H, Kobayashi J (2004) Nankakurine A, a Novel C16N2-Type Alkaloid from Lycopodium hamiltonii. Org Lett 6(19):3389-3391. doi:10.1021/ol048621a
87. Xu SS, Gao ZX, Weng Z, Du ZM, Xu WA, Yang JS, Zhang ML, Tong ZH, Fang YS, Chai XS, Li SL (1995) Efficacy of tablet huperzine A on memory, cognition, and behavior in Alzheimer’s disease. Acta Pharmacol Sin 16:391-395
88. Zhang ZX, Wang XD, Chen QT, Shu L, Wang JZ, Shan GL (2002) Clinical efficacy and safety of huperzine A in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Zhonghua Yi Xue Za Zhi 82:941-944
89. Yang CY, Lu ZP, Zheng CG (2003) Efficacy and reliability of huperzine A in mild to moderate Alzheimer’s disease. Chinese Journal of Clinical Rehabilitation 7:4258-4259
90. Zhang ML, Yuan GZ, Yao JJ, Bi P, Ni SQ (2006) Evaluation of clinical effect and safety of huperzine A in treating 52 Alzheimer’s disease. Zhongguo Xinyao Yu Linchuang Zazhi 25(9):693-695
91. Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Thomas R, Aisen PS, Alzheimer’s Dis Cooperative S (2011) A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 76(16):1389-1394